Storm Therapeutics

Storm Therapeutics, is a spin-out company from the University of Cambridge’s Gurdon Institute focused on the identification and development of small molecule drugs that target RNA-modifying enzymes, opening up novel therapeutic targets in cancer treatment. Storm Therapeutics is based in Cambridge, UK.

http://www.stormtherapeutics.com

Team Member
more about
Hakan Goker
Managing Director
Latest News Entry
2023/01/25
STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference

Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models
STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors

2023/01/10
STORM Therapeutics Expands R&D Leadership Team

TORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces the appointment of Matthew Fyfe as Senior Vice President of Therapeutics and the promotion of Beth Thomas to Vice President of Medicinal Chemistry.

2022/12/14
STORM Therapeutics announces closing of USD $30M Series B financing

STORM Therapeutics announces closing of USD $30M Series B financing

  • Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias
  • Financing will further expand STORM’s novel discovery platform to create additional products targeting RNA modification
2022/09/12
Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

2022/09/07
STORM Therapeutics Appoints New CEO

STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer

2021/03/08
STORM Therapeutics Expands Scientific Advisory Board with the Appointment of Professor Tsutomu Suzuki

STORM Therapeutics today announces the appointment of Professor Tsutomu Suzuki to its Scientific Advisory Board (SAB)

2020/10/22
STORM Therapeutics selects first-in-class clinical candidate targeting METTL3

STORM Therapeutics today announces that STC-15, its first-in-class drug candidate targeting METTL3, has been selected for development towards first in human clinical studies

2018/03/27
STORM Therapeutics wins Life Science Innovation Award

STORM Therapeutics today announced that it has won the Life Science Innovation Award at the Business Weekly Awards ceremony

2018/01/29
STORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific Advisor

STORM today announced the appointment of Nobel Prize Winner professor Thomas Cech as a Scientific Advisor

2018/01/09
STORM Therapeutics Extends Series A Round to Include New Investor Taiho Ventures

Taiho Ventures First Investment in Europe

2017/12/11
STORM Therapeutics Announces Appointments to Scientific Advisory Board

STORM Therapeutics, the leading drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of both Professor Mark Dawson and Dr Paul Leeson to the Scientific Advisory Board.

2017/11/27
STORM THERAPEUTICS ANNOUNCES PUBLICATION IN NATURE ON RNA EPIGENETICS BY FOUNDER PROFESSOR TONY KOUZARIDES

New Drug Target Discovered For Acute Myeloid Leukaemia

STORM Therapeutics, the leading drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the publication of data in the internationally renowned scientific journal Nature linking an essential RNA-modifying enzyme to acute myeloid leukaemia (AML)

2017/11/06
STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research

STORM Therapeutics, the drug discovery company focused on the
discovery of small molecule therapies modulating RNA epigenetics, today announced the
appointment of Professor Paul Workman to its Board. This appointment continues STORM’s evolution
of its management and advisory networks as it fulfils its ambition to become the leading therapeutics
company in RNA epigenetic modulation.

2017/10/26
Taking RNA epigenetics by Storm

Storm is tapping the nascent field of RNA epigenetics for cancer

2017/07/27
Storm Therapeutics expands collaboration with Evotec on Storm's RNA Epigenetics Platform

STORM Therapeutics and Evotec to exploit RNA modulating enzymes for novel epigenetic drug discovery

2017/02/24
Storm Therapeutics appoints CEO and Chairman

CAMBRIDGE, UK (24 FEB 2017) - Storm Therapeutics, the drug discovery company focused on the discovery of small molecule therapies from RNA epigenetics, moved to the next stage of its development with the appointment of Keith Blundy as Chief Executive Officer and Tim Edwards as Chairman.

2016/06/28
Storm Therapeutics raises £12 million Series ‘A’ funding to target enzymes that modify RNA to generate novel cancer therapeutics

Storm Therapeutics raises £12 million Series ‘A’ funding to target enzymes that modify RNA to generate novel cancer therapeutics
28 June 2016
Cambridge, UK - Storm Therapeutics, a spin-out company from the University of Cambridge’s Gurdon Institute focused on the identification and development of small molecule drugs that target RNA-modifying enzymes, has secured £12 million in series ‘A’ funding from Imperial Innovations, Cambridge Innovation Capital, M Ventures and Pfizer Venture Investments.
Storm Therapeutics is based upon the ground-breaking work of its founders, Professor Tony Kouzarides and Professor Eric Miska, in the field of RNA epigenetics.

all related news
all portfolio news